{"entity":{"id":"nct06469879","kind":"trial","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","aka":[],"tldr":"A phase 3 trial of benmelstobart and anlotinib in lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., not yet recruiting.","summary":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients is a phase 3, randomised interventional study registered as NCT06469879 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with a registry enrolment figure of 358 participants, started 2024-09 and due to reach its primary completion in 2026-09. Interventions recorded: TQB2450+Anlotinib; TQB2450 placebo + Anlotinib placebo. Conditions listed: Small Cell Lung Cancer Limited Stage. Primary outcome: Progression-free survival (PFS) evaluated by the Independent Review Committee (IRC). Lung eligibility wording from the registry: \"* Pathologically confirmed patients with limited stage small cell lung cancer (according to the Veterans Administration Lung Study Group (VALG) stage);\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06469879","url":"https://clinicaltrials.gov/study/NCT06469879"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["limited-stage-sclc"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["benmelstobart","anlotinib"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06469879","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Combined With Anlotinib as Maintenance Therapy in Patients With Limited-stage Small Cell Lung Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","enrolled":358,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06469879/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}